CSL LIMITED (CSL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CSL - CSL LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 3.28
Index: ASX20 | ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

CSL is a global biotechnology company that researches, develops, manufactures and markets products for the treatment of human diseases. With a market cap of over $138bn it is one of Australia's top three largest index weights. The former Commonwealth Serum Laboratory listed in June 1994 and has generated an average annual return of 28% since (up until mid-2020). CSL is the world's largest collector of plasma and the second largest producer of vaccines.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$297.50

04 Jul
2024

2.600

OPEN

$297.44

0.88%

HIGH

$299.00

541,262

LOW

$297.16

TARGET
$321.733 8.1% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
CSL: 1
Title FY24
Forecast		 FY25
Forecast
EPS (cps) 936.6 xxx
DPS (cps) 403.8 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 32.0 xxx
Dividend Yield 1.3% xxx
Div Pay Ratio(%) 43.1% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.24%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.17

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 11/03 - ex-div 182.57c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx691.9
DPS All xxxxxxxxxxxxxxx362.9
Sales/Revenue xxxxxxxxxxxxxxx19,585.3 M
Book Value Per Share xxxxxxxxxxxxxxx4,916.4
Net Operating Cash Flow xxxxxxxxxxxxxxx3,866.8 M
Net Profit Margin xxxxxxxxxxxxxxx17.03 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx14.86 %
Return on Invested Capital xxxxxxxxxxxxxxx9.64 %
Return on Assets xxxxxxxxxxxxxxx6.98 %
Return on Equity xxxxxxxxxxxxxxx14.86 %
Return on Total Capital xxxxxxxxxxxxxxx10.85 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx428.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx1,585 M
Long Term Debt xxxxxxxxxxxxxxx16,784 M
Total Debt xxxxxxxxxxxxxxx18,369 M
Goodwill - Gross xxxxxxxxxxxxxxx12,137 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx2,326 M
Price To Book Value xxxxxxxxxxxxxxx5.64

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx2,515.4 M
Capex % of Sales xxxxxxxxxxxxxxx12.84 %
Cost of Goods Sold xxxxxxxxxxxxxxx10,120 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx5,105 M
Research & Development xxxxxxxxxxxxxxx1,836 M
Investments - Total xxxxxxxxxxxxxxx260 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.9

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

15/05/2024

1

Buy

$330.00

10.92%

UBS analysts have spotted a positive development for CSL in a partner's market update.

CSL's partner Terumo confirmed at its Q4 results yesterday it has rolled out the new Rika platform in 60 US plasma collection centres (up from 40 when the analysts toured CSL's Melbourne facilities in April).

The analysts explain this means CSL's target for 60 by the end of FY24 has been met slightly early.

As per the broker, Rika will give CSL advantages like shorter donation times for patients and increases plasma yield via the use of a
personalised nomogram. The broker considers this a positive development and expects the market to do so too.

The remaining centres (circa 240) are set to be deployed in FY25. Buy. Target $330.

FORECAST
UBS forecasts a full year FY24 dividend of 396.46 cents and EPS of 959.13 cents.
UBS forecasts a full year FY25 dividend of 436.11 cents and EPS of 1136.02 cents.

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

CSL STOCK CHART

FNArena News on CSL

1
Rudi’s View: Met Coal, Banks, GenAi & Buying-The-Dip

Jul 04 2024 - Rudi's View
2
June In Review: FY24 Another Double Digit Return

Jul 03 2024 - Australia
3
Rudi’s View: Copper, Lithium, Retailers & TechnologyOne

Jun 27 2024 - Rudi's View
4
Rudi’s View: Traditional Value Is A Flawed Narrative

Jun 26 2024 - Rudi's View
5
Rudi’s View: GenAi, The Super-Megatrend, Part 2

Jun 20 2024 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
2
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
3
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps
4
Is The Long Wait For CSL About To End?

May 30 2024 - Technicals
5
Dr Boreham’s Crucible: Invion

May 13 2024 - Small Caps
6
Dr Boreham’s Crucible: Race Oncology

Apr 09 2024 - Small Caps
7
The Power Of New Weight-Loss Drugs

Apr 03 2024 - International
8
Dr Boreham’s Crucible: Neuren Pharmaceuticals

Mar 11 2024 - Small Caps
9
Spotlight On ASX-Listed Cannabis Companies

Jan 31 2024 - Small Caps
10
Transformational Trial Results For Neuren Pharmaceuticals

Dec 20 2023 - Small Caps